Weekly Recap | Skye Bioscience -44.09%, consensus target far above spotWeekly Review·8 hours agoSKYE-0.14%
5AM Partners VII disposes of 375,840 Skye Bioscience shares worth $134,482.80PUBT·1 day ago, 04:57 PMSKYE-0.14%
Skye Bio amends 8-K to set Aug. 24 effective date for reverse stock splitPUBT·2 days ago, 05:07 AMSKYE-0.14%
Skye Bioscience flags Nasdaq noncompliance after stockholders’ equity falls to ($497,307)PUBT·Aug 19 at 05:04 AMSKYE-0.14%
Pre-market hot trades in US stocks: Skye Bioscience down 8.36% in pre-market; Cerebras down 3.05% in pre-marketPrice Alert·Aug 18 at 07:18 AMSKYE-0.14%CBRS-6.54%
U.S. stock night market opening fluctuations: Steakholder Foods fell 6.31% in the night market; Skye Bioscience rose 5.28% in the night marketPrice Alert·Aug 17 at 07:12 PMSTKH-9.16%SKYE-0.14%
Pre-market hot trades in US stocks: Skye Bioscience up 41.50% in pre-market; IP Strategy up 38.18% in pre-marketPrice Alert·Aug 17 at 03:02 AMSKYE-0.14%IPST-6.40%
U.S. stock night market opening fluctuations: Skye Bioscience rose 28.95% in the night market; Generation Income Properties fell 26.40% in the night marketPrice Alert·Aug 16 at 07:07 PMSKYE-0.14%GIPR+2.84%
U.S. stock night market volatility: Skye surged 29% in after-hours trading: plans to merge with Redx to raise $125 million, betting on the fibrosis sectorPrice Alert·Aug 16 at 07:06 PMSKYE-0.14%
SKYE: Terminated nimacimab R&D, pursuing Redx Pharma acquisition, facing liquidity and Nasdaq risksQuartr·Aug 14 at 08:43 AMSKYE-0.14%
Skye Bioscience Q2 2026 operating loss narrows 39.37% to $11.06 millionPUBT·Aug 14 at 08:40 AMSKYE-0.14%
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings | SKYE Stock NewsStockTitan·Aug 14 at 12:33 AMSKYE-0.14%
